1989
DOI: 10.1161/01.cir.79.1.8
|View full text |Cite
|
Sign up to set email alerts
|

High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies.

Abstract: The British Regional Heart Study (BRHS) reported in 1986 that much of the inverse relation of high-density lipoprotein cholesterol (HDLC) (MRFIT). In CPPT and MRFIT (both randomized trials in middle-aged high-risk men), only the control groups were analyzed. A 1-mg/dl (0.026 mM) increment in HDLC was associated with a significant coronary heart disease risk decrement of 2% in men (FHS, CPPT, and MRFIT) and 3% in women (FHS). In LRCF, where only fatal outcomes were documented, a 1-mg/dl increment in HDLC was… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

45
1,366
11
58

Year Published

1993
1993
2008
2008

Publication Types

Select...
10

Relationship

0
10

Authors

Journals

citations
Cited by 2,800 publications
(1,513 citation statements)
references
References 29 publications
45
1,366
11
58
Order By: Relevance
“…In observational studies, HDLc is a negative, independent CHD risk factor with a dose-response relationship [29], consistent with the classical risk factor concept. However, it is possible that a threshold exists for the protective effect of HDLc [30].…”
Section: Discussionsupporting
confidence: 73%
“…In observational studies, HDLc is a negative, independent CHD risk factor with a dose-response relationship [29], consistent with the classical risk factor concept. However, it is possible that a threshold exists for the protective effect of HDLc [30].…”
Section: Discussionsupporting
confidence: 73%
“…From a meta-analysis of four prospective epidemiologic studies, an increase in 1 mg/dl HDL-C was equated with an independent reduction in the incidence of coronary events of 2% in men and 3% in women. 47 However, similar estimates of benefit have been derived from studies with cholestyramine (Lipid Research Clinics Prevention Trial) and gemfibrocil (Helsinki Heart Study), where a 1% increase in HDL-C was associated with 0.6 and 2-3% decrease in CHD events, respectively. 48 Furthermore, evidence from the large statinintervention studies (CARE, LIPID) showed that baseline HDL-C modulated the clinical event rate despite a similar lowering of LDL-C. 27 Taken together, the ability to predict an increase in HDL, or to identify HDL-C low responders during statin therapy will be of clinical relevance.…”
Section: Clinical Relevancementioning
confidence: 71%
“…Controlled clinical trials have estimated that for every 1% reduction in total and LDL cholesterol concentrations, there is a approximately 1.5% reduction in the incidence of CHD (Davis et al, 1990;NCEP, 1993). Moreover, coronary events are reduced by 2-3% for every 1 mg/dl increase in HLD cholesterol (Gordon et al, 1989). Thus, an increase of 89 mg/dl in TAG concentrations is associated with a 14% increase in the incidence of CHD in men and a 37% increase in women (Austin et al, 1998).…”
Section: Effects Of Hazelnut-enriched Diet On Plasma Lipid Profiles Smentioning
confidence: 99%